The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
dc.contributor.author | Pors, Klaus | * |
dc.contributor.author | Goldberg, F.W. | * |
dc.contributor.author | Leamon, C.P. | * |
dc.contributor.author | Rigby, A.C. | * |
dc.contributor.author | Snyder, S.A. | * |
dc.contributor.author | Falconer, Robert A. | * |
dc.date.accessioned | 2016-08-17T14:34:07Z | |
dc.date.available | 2016-08-17T14:34:07Z | |
dc.date.issued | 2009-11 | |
dc.identifier.citation | Pors K, Goldberg FW, Leamon CP, Rigby AC, Snyder SA, Falconer RA (2009) The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discovery Today, 14 (21/22): 1045-50. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/8821 | |
dc.description | no | en_US |
dc.description.abstract | Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists. | en_US |
dc.language.iso | en | en_US |
dc.relation.isreferencedby | http://www.sciencedirect.com/science/article/pii/S1359644609002323 | en_US |
dc.subject | Cancer drug discovery; Medicinal chemistry; Chemical biology; Diversity-oriented synthesis; EPSRC; Government funding; NCI | en_US |
dc.title | The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow | en_US |
dc.status.refereed | Yes | en_US |
dc.type | Article | en_US |
dc.type.version | published version paper | en_US |